Showing results (1-10 of 201) with videos related to
Sort By:
Pageof 21
Clinical Drug Investigation|January 5, 2024
Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization ApproachesJeffrey H LiptonHaematologica|July 10, 2025
Advancing quality of life research in chronic myeloid leukemia: where do we stand?Jeffrey H LiptonAmerican Journal of Blood Research|July 21, 2025
Acute myolysis in patients on tyrosine kinase inhibitor therapy for chronic myeloid leukemiaJeffrey H LiptonClinical Transplantation|May 6, 2025
Allorgafting for Aplastic Anemia on a Background of HELLP Syndrome in Identical TwinsJeffrey H LiptonLeukemia Research|January 31, 2017
Current approach to the treatment of chronic myeloid leukaemiaIvan Pasic, Jeffrey H LiptonClinical Lymphoma, Myeloma & Leukemia|October 8, 2013
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phaseElias Jabbour, Jeffrey H LiptonLeukemia & Lymphoma|September 8, 2021
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort studyAniket Bankar, Jeffrey H LiptonLeukemia & Lymphoma|February 9, 2024
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not goneKenny Tang, Jeffrey H LiptonAmerican Journal of Hematology|April 16, 2026
The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase InhibitorsIvan Pasic, Jeffrey H LiptonAmerican Journal of Hematology|April 13, 2026
Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-MakingArjun Datt Law, Jeffrey H LiptonPageof 21